WALPAR NUTRITIONS LIMITED (WALPAR): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹24.35 latest close · −41.5% over the last 90 sessions

₹24.35 month-end · −38.9% over 12 months

₹24.35 month-end · −42.7% over 3 years

₹24.35 month-end · +24.6% since Jul '21

52-week range ₹21.25 to ₹53.30 · 1-year volatility 55.4%

Was the rally earned?

-39%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

Per-share earnings added 5 points, but investors now pay less per rupee of profit (P/E 16.0x to 9.3x), which took 43 points back.
The share count barely moved.

Net profit growth+5 ptsNet profit rose about 7%, which lifts the price.

P/E change-43 ptsThe P/E fell from 16.0x to 9.3x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with CIPLA

How rough has the ride been?

Maximum drawdown-70.0%not yet recovered

1-year volatility55.4%annualised

Drawdown from peak

Largest drawdowns

-70.0% (2024-01 peak to 2026-09 low, not yet recovered)

-54.0% (2021-07 peak to 2022-03 low, recovered 2022-08)

-37.1% (2022-09 peak to 2023-03 low, recovered 2023-05)

Is it expensive against its own past and its peers?

9.3xP/E todayNear its historic low

Against its own history2nd percentile

CheapestMedian 61.0xDearest

Usual range 13.7x to 88.0x since 2021-07.

Against Health Technology9.3x vs 37.0x

This company

9.3x

Sector median

37.0x

75% below the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE50th▼ 9 pts vs a year ago
Revenue growth43rd▼ 29 pts vs a year ago
EPS growth48th▼ 36 pts vs a year ago
Debt/equity ↓9th▼ 16 pts vs a year ago
Cash cycle ↓82ndflat vs a year ago
P/E ↓95th▲ 8 pts vs a year ago
12M momentum2nd▼ 37 pts vs a year ago

Rank history

ROCE

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~7%annual earnings growth implied by the price

At a P/E of 9.3x, the price would imply about 6.7%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 8 Nov: ₹24.35
P/E: 9.3x
ROCE: 14.8%
Market Cap: ₹23 cr
Revenue (TTM): ₹79 cr
P/S: 0.3x
P/B: 1.2x
ROE: 13.1%
Debt / Equity: 0.9x
Promoter Holding: 68.8%
12M Momentum: -38.9%

52-week range

₹21.25₹53.30

10% of the way from its 52-week low to its high

Price risk

1Y volatility

55.4%

Beta vs sector

1-year daily

0.56

Balance sheet & cash

Interest cover

operating profit ÷ interest

6.1x

Cash from profit, 3Y

operating cash flow ÷ net profit

1.45x

Share count, 1Y

unchanged

Are profits backed by cash?

4 of 6checks within range2 near a threshold

Other income reliance6%Within range

Other income as a share of pre-tax profit (trailing twelve months): 6.3%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion1.45xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.45x (cash from operations ₹11.2 cr, net profit ₹7.7 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+1 daysWithin range

Debtor days are above the median of the previous three fiscal years by 1 days (109 vs 108). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress0% of fixed assetsWithin range

Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+63 days / 2 yrsNear threshold

Days payable changed by +63 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, promoters trimmed 1.7 pts.
The number of shareholders fell from 496 to 327 (-34%) between Sep 2021 and Mar 2026.

Holdings, Mar '26

How each group changed

GroupSep '21Mar '26Change

Promoters71.0%68.8%-2.2 pts

FIIs———

DIIs———

Public and others29.0%31.2%+2.2 pts

Number of shareholders

327shareholders-34% since Sep '21

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+4.1%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like WALPAR NUTRITIONS LIMITED today on valuation, return on capital, debt, growth, price momentum and size.
Over the following 12 months the middle half of them returned −18% to +41% vs the market, against −6% for all non-financial companies in the same months.
The gap against the base rate (+9.9%, 80% range −2.3% to +22.8%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 6 beyond the range shown, drawn at the edge

Similar setups' median

+4.1%

All companies' median

−5.8%

Beat the market

52% vs 44%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GEEKAYWIRE Producer Manufacturing	Apr 2022	12x	13%	−7%	−35%	+140%
HISARMETAL Non-Energy Minerals	Jan 2022	12x	14%	+16%	−28%	+35%
CENTEXT Producer Manufacturing	Feb 2020	6x	14%	−60%	−63%	+32%
AMDIND Process Industries	May 2021	7x	10%	+26%	−18%	+120%
NAGREEKEXP Process Industries	Jul 2025	—	—	−37%	−57%	−18%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
AIROLAM Non-Energy Minerals	May 2021	8x	—	+33%	−24%	+134%
UMA Process Industries	Jun 2024	13x	9%	−7%	−37%	−4%
PRECISION Non-Energy Minerals	Feb 2025	10x	9%	−44%	−56%	−73%

How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high and size. Closest on: 12-month momentum, P/S and P/E. Not used (unavailable for this company): operating margin and volatility. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to WALPAR NUTRITIONS LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

22 events since Mar '22

2026
SepPriceFell 70% from the Jan 2024 peak to the Sep 2026 low.
SepPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
AugPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).
JunResultsRevenue (TTM) reached a new high of ₹79 cr.
JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
AprValuationP/E fell below the 10th percentile of its own history to date (15.0x).
2025
JunResultsRevenue (TTM) reached a new high of ₹72 cr.
JunPeer rankMoved into the 2nd quartile of Health Technology on ROCE (from the 3rd quartile).

Show 14 earlier events

2024
DecPromoterPromoter holding fell 2.8 pts to 68.4% (largest drop in the history since 2019-01).
JunResultsRevenue (TTM) reached a new high of ₹63 cr.
JunValuationP/E fell below the 10th percentile of its own history to date (31.1x).
JanValuationP/E crossed above the 90th percentile of its own history to date (111.4x).
2023
JunResultsRevenue (TTM) reached a new high of ₹35 cr.
JunPeer rankMoved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
MayPriceRegained the 2022-09 peak, 2 months after the low.
MarPriceFell 37% from the Sep 2022 peak to the Mar 2023 low.
FebDebtDebt / equity halved over 12 months to 0.66x.
2022
AugPriceRegained the 2021-07 peak, 5 months after the low.
JulDebtDebt / equity halved over 12 months to 0.66x.
JulSharesShare count is up 35.9% over 12 months.
JunDebtDebt / equity fell below 1.0x (0.66x).
MarPriceFell 54% from the Jul 2021 peak to the Mar 2022 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history65 months · 2021-07 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	9.3x	₹79 cr	13.1%	14.8%	0.9x
2026-10	9.5x	₹79 cr	13.1%	14.8%	0.9x
2026-09	10.8x	₹79 cr	13.1%	14.8%	0.9x
2026-08	9.8x	₹79 cr	13.1%	14.8%	0.9x
2026-07	13.3x	₹79 cr	13.1%	14.8%	0.9x
2026-06	10.6x	₹79 cr	13.1%	14.8%	0.9x
2026-05	13.3x	₹72 cr	14.0%	16.1%	0.5x
2026-04	15.0x	₹72 cr	14.0%	16.1%	0.5x
2026-03	—	—	—	—	—
2026-02	—	—	—	—	—
2026-01	18.4x	₹72 cr	14.0%	16.1%	0.5x
2025-12	19.4x	₹72 cr	14.0%	16.1%	0.5x
2025-11	16.0x	₹72 cr	14.0%	16.1%	0.5x
2025-10	17.8x	₹72 cr	14.0%	16.1%	0.5x
2025-09	16.1x	₹72 cr	14.0%	16.1%	0.5x
2025-08	17.9x	₹72 cr	14.0%	16.1%	0.5x
2025-07	19.0x	₹72 cr	14.0%	16.1%	0.5x
2025-06	20.6x	₹72 cr	14.0%	16.1%	0.5x
2025-05	28.8x	₹63 cr	5.6%	12.8%	0.6x
2025-04	27.4x	₹63 cr	5.6%	12.8%	0.6x
2025-03	25.2x	₹63 cr	5.6%	12.8%	0.6x
2025-02	26.2x	₹63 cr	5.6%	12.8%	0.6x
2025-01	29.6x	₹63 cr	5.6%	12.8%	0.6x
2024-12	30.1x	₹63 cr	5.6%	12.8%	0.6x
2024-11	31.2x	₹63 cr	5.6%	12.8%	0.6x
2024-10	29.7x	₹63 cr	5.6%	12.8%	0.6x
2024-09	29.4x	₹63 cr	5.6%	12.8%	0.6x
2024-08	39.0x	₹63 cr	5.6%	12.8%	0.6x
2024-07	35.1x	₹63 cr	5.6%	12.8%	0.6x
2024-06	31.1x	₹63 cr	5.6%	12.8%	0.6x
2024-05	98.2x	₹35 cr	2.5%	8.8%	0.9x
2024-04	106.2x	₹35 cr	2.5%	8.8%	0.9x
2024-03	80.9x	₹35 cr	2.5%	8.8%	0.9x
2024-02	94.3x	₹35 cr	2.5%	8.8%	0.9x
2024-01	111.4x	₹35 cr	2.5%	8.8%	0.9x
2023-12	63.5x	₹35 cr	2.5%	8.8%	0.9x
2023-11	73.1x	₹35 cr	2.5%	8.8%	0.9x
2023-10	66.7x	₹35 cr	2.5%	8.8%	0.9x
2023-09	65.4x	₹35 cr	2.5%	8.8%	0.9x
2023-08	71.5x	₹35 cr	2.5%	8.8%	0.9x
2023-07	63.5x	₹35 cr	2.5%	8.8%	0.9x
2023-06	55.8x	₹35 cr	2.5%	8.8%	0.9x
2023-05	92.9x	₹27 cr	1.7%	4.8%	0.7x
2023-04	83.1x	₹27 cr	1.7%	4.8%	0.7x
2023-03	60.1x	₹27 cr	1.7%	4.8%	0.7x
2023-02	61.0x	₹27 cr	1.7%	4.8%	0.7x
2023-01	78.6x	₹27 cr	1.7%	4.8%	0.7x
2022-12	75.0x	₹27 cr	1.7%	4.8%	0.7x
2022-11	69.5x	₹27 cr	1.7%	4.8%	0.7x
2022-10	64.8x	₹27 cr	1.7%	4.8%	0.7x
2022-09	71.4x	₹27 cr	1.7%	4.8%	0.7x
2022-08	72.5x	₹27 cr	1.7%	4.8%	0.7x
2022-07	65.2x	₹27 cr	1.7%	4.8%	0.7x
2022-06	40.4x	₹27 cr	1.7%	4.8%	0.7x
2022-05	90.0x	₹6 cr	1.5%	—	1.6x
2022-04	84.5x	₹6 cr	1.5%	—	1.6x
2022-03	61.4x	₹6 cr	1.5%	—	1.6x
2022-02	65.7x	₹6 cr	1.5%	—	1.6x
2022-01	64.1x	₹6 cr	1.5%	—	1.6x
2021-12	66.8x	₹6 cr	1.5%	—	1.6x
2021-11	69.5x	₹6 cr	1.5%	—	1.6x
2021-10	72.5x	₹6 cr	1.5%	—	1.6x
2021-09	78.2x	₹6 cr	1.5%	—	1.6x
2021-08	78.6x	₹6 cr	1.5%	—	1.6x
2021-07	88.9x	₹6 cr	1.5%	—	1.6x

Methodology and data notes